Intended for healthcare professionals


Update to living WHO guideline on drugs for covid-19

BMJ 2022; 378 doi: (Published 13 July 2022) Cite this as: BMJ 2022;378:o1713

This living guideline by Agarwal and colleagues (BMJ 2020;370:m3379) has been updated. For the latest update, visit doi:10.1136/bmj.m3379. The latest version of this WHO living guidance provides two new recommendations for patients with non-severe covid-19: (a) a recommendation against the use of fluvoxamine except in the context of a clinical trial; (b) a strong recommendation against the use of colchicine. No recommendation was made for either drug in patients with severe or critical illness, given limited or no data.